AstraZeneca’s investigational ATR kinase inhibitor did not improve overall survival when combined with Imfinzi in patients with non-small cell lung cancer during a Phase III clinical trial, the ...

E73, which is designed to treat several KRAS mutation subtypes, and is testing the therapy in multiple Phase I trials.

The biologics center director reportedly became personally involved after the team reviewing the rare blood disorder filing asked for an extension to the CNPV-accelerated timeline.

Leerink analysts hailed the deals as a sign that President Trump “is unlikely to attack the industry in 2026.” ...

The biotech, which has a deal with Eli Lilly worth as much as $1.1 billion, is developing two targeted radiopharmaceuticals from its miniprotein radioconjugate platform.

Stifel analysts said the label for cardiac myosin inhibitor Myqorzo is in line with their expectations and is differentiated compared with BMS’ Camzyos.

BMO pointed to Gilead, Eli Lilly, Regeneron and Merck from the pharma world as names to watch for 2026. “With what felt like sector whiplash in 2025, we remain optimistic into 2026,” the team’s ...

Policy initiatives have come fast and furious at the FDA this year. While guidances on rare diseases and vaccines have consumed most of the ink, policy shifts aimed at improving FDA efficiencies and ...

San Diego–based Ventyx Biosciences has what pharma wants, according to William Blair: two NLRP3 inhibitors for inflammatory ...

These deals radically reshaped the biopharma world, either by one vaccine rival absorbing another, a Big Pharma doubling down ...

Pfizer CEO Albert Bourla defended his company’s vaccine business as rhetoric from HHS Secretary Robert F. Kennedy Jr. drives ...

Despite falling short of its primary Phase II objective, Nektar plans to push its T cell stimulator rezpeg into Phase III ...